British Journal of Dermatology · 2005 · 51 citations · 31 references
MedicineDermatologyImmunologyClinical EpidemiologyClinical ImmunologyImmunopathologyHematologic PathologyImmuno-oncology BiomarkersCd8 Positive T CellsClinical Grading SystemsImmunological AssaysKaplan-meier Survival EstimatesLaboratory MarkersNeutrophil-to-lymphocyte RatioSurvival Probability EstimationTumor Stage Mycosis Fungoides
BACKGROUND: There is a need for reliable, easily measurable laboratory markers that may help dermatologists to predict the course of mycosis fungoides (MF) when they first evaluate their patients. OBJECTIVES: Our objective was to identify clinical, haematological or immunological parameters as predictors of mortality in patients with MF. METHODS: We conducted a retrospective study on a prevalent cohort of 124 patients with MF hospitalized at IDI-IRCCS, Rome, Italy, from 1983 to 2001. We calculated the proportion of patients surviving (Kaplan-Meier product-limit estimates) 5 and 10 years after first hospital admission, and hazard ratios (HR) from the Cox proportional hazards model. RESULTS: Patients' survival was linked to age and staging (lower survival in older patients and in patients with staging IIB-IV). Higher numbers of white blood cells (WBC) and neutrophils, lower numbers of CD8+ lymphocytes, low haematocrit and lower levels of albumin were significantly associated with a lower survival probability. When simultaneously accounting for age and staging, CD8+ [HR = 3.02, 95% confidence interval (CI) 1.01-9.07 for CD8+ < 250 vs. > or = 600 cells microL(-1)] and WBC (HR = 2.59, 95% CI 0.96-6.96 for WBC > or = 9000 vs. < 6000 cells microL(-1)) were associated with survival. In addition, we observed an exceedingly high risk of death (HR = 12.40, 95% CI 3.11-49.43) for patients with a combination of WBC > or = 9000 and CD8+ < 600 cells microL(-1) vs. WBC < 9000 and CD8+ > or = 600 cells microL(-1)). CONCLUSIONS: The measurement of CD8+ cells and WBC in MF seems to be a promising criterion to predict survival, and possibly to support treatment decisions and inclusion of patients in randomized controlled trials.
31
Statistical Models and Methods for Lifetime Data
Ray E. Schafer, J. F. Lawless · Technometrics · 1983 · 1.5K citations
Public Health, Biostatistics, Aging +13
Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome
Youn H. Kim, Howard L. Liu, Serena Mraz‐Gernhard et al. · Archives of Dermatology · 2003 · 652 citations
Medicine, Dermatology, Oncology +16